Therapeutic Solutions International Collaborates with
Internationally Renowned Neurologist and NFL
Charger Hall of Famer to Develop New
Intellectual Property for Treatment of Chronic Traumatic
Encephalopathy
Company Files Patent and Generates Proof of Concept Data using
NeuroStilbene for Prevention of Football Associated Brain
Damage
OCEANSIDE, CA --
September 19, 2018 -- InvestorsHub NewsWire --
Therapeutics
Solutions International, Inc., (OTC Markets:
TSOI) announced today new
data demonstrating the ability of its NeuroStilbene intranasal
formulation of pterostilbene to successfully prevent the
development of brain injury in an animal model of Chronic Traumatic
Encephalopathy.
Through a
collaboration with its Scientific Advisory Board Member Dr.
Santosh Kesari, and NFL Chargers Hall of Famer Wes Chandler, the
Company has filed a patent covering these new findings and means of
utilizing pterostilbene based formulations for prevention and
treatment of Chronic Traumatic Encephalopathy.
"The current data
provided in the patent strongly supports the possibility that
receiving NeuroStilbene before sports-related brain injuries will
prevent the development of Chronic Traumatic Encephalopathy," said
Wes Chandler, Chairman of the TSOI CTE Advisory
Board. "As someone who
personally suffers from Chronic Traumatic Encephalopathy,
including depression, memory
loss, hand tremors, and a loss even of my
penmanship, I can speak first
hand on the urgent need to provide players with medical solutions
to prevent the development of CTE. It is our
intention to add additional athletes who suffer from similar types
of ailments from all sports and not just football
to the
CTE Advisory Board. This is not
about abolishing
professional sports entities, but
an attempt to collaborate for prevention and treatment of this
terrible condition."
Chronic Traumatic
Encephalopathy is a major problem in football, other
contact
sports, and military veterans. This condition has
been seen in people as young as 17, but symptoms do not
generally
begin appearing until years
after the onset of head impacts. Common symptoms of Chronic
Traumatic Encephalopathy in the early stages of the condition
include impulse control problems, aggression, depression, and
paranoia. As the disease progresses, some patients may experience
problems with thinking and memory, including memory loss,
confusion, impaired judgment, and eventually progresses to
dementia.
"NeuroStilbene is a
nanotechnology-based formulation of pterostilbene which is produced
from naturally occurring ingredients and is currently available for
purchase as a nutraceutical. Although our recent data demonstrates
a reduction in tau and suppression of brain cell damage with
NeuroStilbene, clinical trials are needed before specific medical
claims can be made," said Dr. James
Veltmeyer, Chief Medical Officer of the Company and Vice Chairman
of the CTE Advisory Board. "That being said, there are numerous
peer reviewed scientific
publications showing pterostilbene protects against brain damage in
a variety of settings. For example, some studies show pterostilbene
suppresses inflammation associated memory decline [1,2], other
studies show pterostilbene suppresses hemorrhagic brain injury and
neuronal cell death[3,4]
and yet other ones show protection of the brain against damage
associated with lack of oxygen and aging[5,6,7]. Given all this
supporting data, it is a logical extension to believe that
NeuroStilbene, which is a more potent formulation of pterostilbene,
would possess activity against Chronic Traumatic
Encephalopathy."
Previous clinical
studies by the Company have demonstrated that NanoStilbene
possesses superior distribution and half-life of pterostilbene when
administered to healthy volunteers.
"The filing of
today's patent represents a successful collaboration between
medical, basic research, and sports experts," said Timothy Dixon,
President, and CEO of TSOI. "It is our honor to work with experts
such as Dr. Kesari who understand not only the basic science of how
the healthy and diseased brain works but also possess the medical
insight to translate findings into patients."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
1. Naik et al.
Pterostilbene ameliorates intracerebroventricular
streptozotocin induced memory decline in rats.
Cogn
Neurodyn.
2017 Feb;11(1):35-49. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264756/
2. Hou
et
al. Pterostilbene attenuates
lipopolysaccharide-induced learning and memory impairment
possibly via inhibiting microglia
activation and protecting neuronal injury in
mice. Prog
Neuropsychopharmacol
Biol
Psychiatry.
2014 Oct 3;54:92-102.
https://www.ncbi.nlm.nih.gov/pubmed/24709550
3. Liu et al.
Pterostilbene Attenuates Early Brain Injury Following
Subarachnoid Hemorrhage via Inhibition of the NLRP3 Inflammasome
and Nox2-Related Oxidative Stress. Mol
Neurobiol.
2017 Oct;54(8):5928-5940. https://www.ncbi.nlm.nih.gov/pubmed/27665283
4. Wang et al.
Neuroprotective effects of pterostilbene against oxidative
stress injury: Involvement of nuclear factor erythroid 2-related
factor 2 pathway. Brain Res. 2016
Jul 15;1643:70-9.
https://www.ncbi.nlm.nih.gov/pubmed/27107941
5. Chang et al.
Low-dose pterostilbene, but not resveratrol, is a potent
neuromodulator in aging and Alzheimer's disease.
Neurobiol
Aging.
2012 Sep;33(9):2062-71. https://www.ncbi.nlm.nih.gov/pubmed/21982274
6. Cherniack
et
al. A berry thought-provoking idea: the potential
role of plant polyphenols in the treatment of age-related cognitive
disorders. Br J
Nutr. 2012 Sep;108(5):794-800.
https://www.ncbi.nlm.nih.gov/pubmed/22475317
7. Yang et al.
HO-1 Signaling Activation by Pterostilbene Treatment
Attenuates Mitochondrial Oxidative Damage Induced by Cerebral
Ischemia Reperfusion Injury. Mol
Neurobiol.
2016 May;53(4):2339-53. https://www.ncbi.nlm.nih.gov/pubmed/25983033
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Oct 2023 to Oct 2024